Study of Anlotinib in Patients With Medullary Thyroid

Updated 06/21/2024

Status Completed

Clinical Trial Summary

To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02586350
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	July 2015
Completion date	September 30, 2018

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT03636945` - Evaluation of 18F-FDOPA PET-CT in the Preoperative Initial Assessment of Medullary Thyroid Carcinoma	N/A
	Withdrawn	`NCT01736878` - Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma	Phase 2
	Completed	`NCT06067594` - Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.
	Active, not recruiting	`NCT04970134` - Spanish Study for Molecular Characterization of Thyroid Carcinoma
	Completed	`NCT01424878` - Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
	Completed	`NCT00514046` - Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer	Phase 1/Phase 2
	Recruiting	`NCT04787328` - A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)	Phase 2
	Completed	`NCT01730638` - ImmunoTEP for Patients With Medullary Thyroid Carcinoma.	Phase 1/Phase 2
	Enrolling by invitation	`NCT01511393` - An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
	Terminated	`NCT00923247` - A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)	Phase 1/Phase 2
	Completed	`NCT00880503` - Collection of Tissue Samples for Study of Multidrug Resistance
	Not yet recruiting	`NCT06121271` - Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications	Phase 2
	Completed	`NCT03246659` - Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC	Phase 1
	Recruiting	`NCT05534594` - Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer	N/A
	Not yet recruiting	`NCT01373736` - 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors	Phase 3